Industry News GSK / Nuvalent BioSpace
GSK's Nelkarmi wins accelerated approval, second drug from the $10.6B Nuvalent buy
- FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated ALK-positive NSCLC, 10 days ahead of its November 27 action date; a confirmatory study is required.
- Approval rests on the Phase 1/2 ALKOVE-1 study: response rates were higher in patients whose only prior ALK inhibitor was Alecensa, with notable intracranial activity. Liver toxicity was the most common reason for discontinuation.
- It follows July's Jideytro (zidesamtinib, ROS1) from the same acquisition.
Two approvals within five months of closing makes the $10.6B Nuvalent price look better than it did in June. But the second-line launch faces Pfizer's Lorbrena, and the real prize is first-line, where the head-to-head against Alecensa is still running; the accelerated label rides on single-arm response data until then. Watch hepatotoxicity in that comparison: it is the first place a clean profile could separate from entrenched rivals.
Source: BioSpace ↗ GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy